NOTE 10: RELATED PARTY TRANSACTIONS

The following is a description of certain relationships and transactions that exist or have existed or that the Company has entered into, in each case since January 1, 2025, with its directors, executive officers, or stockholders who are known to the Company to beneficially own more than ten percent of its voting securities and their respective affiliates and immediate family members.

Sponsor of Monterey Capital Acquisition Corporation (“MCAC”)

In connection with the closing of the Business Combination, the Company assumed unsecured promissory notes totaling approximately $555,000 that are non-interest bearing and due on demand and advances totaling approximately $132,000 that are non-interest bearing and due on demand with the Sponsor of MCAC. During September 2024, the Company entered into a note conversion

agreement with the Sponsor of MCAC in which the Company converted the outstanding principal on unsecured promissory notes and certain other liabilities owed to the note holders into shares of the Company’s common stock at a conversion price of $2.00 per share with a one-time share reset adjustment, subject to shareholder approval and a maximum aggregate ownership amount of 19.99% for each individual lender. In connection with these agreements, approximately $555,000 of unsecured promissory notes and approximately $132,000 of accounts payable and accrued expenses were extinguished in exchange for the issuance of 343,248 shares (pre-split) of the Company’s common stock.

In connection with the conversion agreement, the Sponsor of MCAC received a one-time share reset adjustment that was settled during the quarter ended June 30, 2025 through the issuance of 205,949 shares (pre-split) of the Company’s common stock. The derivative was settled during 2025 and no derivative liability was outstanding as of June 30, 2026. For the three months ended June 30, 2026 and 2025, the Company recorded a change in fair value on these derivative liabilities of ($19,000) and $511,000, respectively and for six months ended June 30, 2026 and 2025, the Company recorded a change in fair value on these derivative liabilities of $39,000 and $544,000, respectively which was included as a component of change in fair value of derivative liabilities on the accompanying condensed consolidated statements of operations and comprehensive loss.

Avanti Notes

In November 2025, in connection with the acquisition of controlling interest in Geo Impex & Logistics Pvt. Ltd., the Company assumed a note payable of approximately $279,000 due to Avanti Holdings LLC (“Avanti”), maturing on October 31, 2026. As part of divestment of India operations, this note was transferred to Blue Cloud.

Total interest expense recognized on the promissory notes with the Related Party Lender was nil for each of the three and six months ended June 30, 2026, and approximately $5,100 and $10,300 for the three and six months ended June 30, 2025, respectively.

Keen Labs Supply and Services Agreement with Sun Solar, LLC

In connection with the equity method investment (Note 5), Keen Labs Operations, Inc. (“Keen Labs”), a wholly-owned subsidiary of the Company, entered into a Supply and Services Master Agreement (the “Keen Labs MSA”) with Sun Solar, effective January 6, 2026, pursuant to which Keen Labs procures and supplies solar panels, inverters, batteries, and related balance-of-system components to Sun Solar at actual invoiced product cost (including procurement and logistics fee) plus marketing and other professional services after adding a mark-up of 10%. The Keen Labs MSA is non-exclusive, terminable by either party upon 30 days’ written notice. Additional services, including marketing, supply chain consulting, and working capital support, may be provided under separate statements of work.

During the three and six months ended June 30, 2026, the Company recognized revenue of approximately $1,966,000 and $3,816,000 respectively and cost of revenue of approximately $1,248,000 and $2,417,000, respectively under the Keen Labs MSA, reported within the Keen Labs segment.

The Company recorded an equity in earnings of Sun Solar of approximately $427,000 and $708,000, respectively for the three and six months ended June 30, 2026, which is included in “Other income (expense), net” in the condensed consolidated statements of operations and comprehensive loss. In accordance with ASC 323-10-35-7, the Company eliminated its proportionate share (40%) of unrealized intra-entity gross profit on Keen Labs products remaining in Sun Solar’s inventory at June 30, 2026, totaling approximately $47,000, which reduced both equity in earnings and the carrying amount of the equity method investment. The carrying value of the Company’s investment in Sun Solar was approximately $7,833,000 as of June 30, 2026.

Shares Issued to Related Parties

During the three and six months ended June 30, 2026, the Company issued 12,695 and 39,101 shares of restricted common stock to its non-employee directors as compensation for board service. The shares were fully vested upon issuance and are subject to customary transfer restrictions under applicable securities laws. The Company recognized approximately $81,000 and $302,000 of stock-based compensation expense, included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss, equal to the grant-date fair value of the awards. The grant dates are March 2, 2026 and April 1, 2026. The grant date fair value was $8.37 and $6.40 for three and six months ended June 30, 2026.

During the three and six months ended June 30, 2025, the Company issued 50,694 shares of restricted common stock to its non-employee directors as compensation for board service. The shares were fully vested upon issuance and are subject to customary transfer restrictions under applicable securities laws. The Company recognized approximately $372,000 of stock-based compensation expense, included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations

and comprehensive loss, equal to the grant-date fair value of the awards. The grant dates are May 27, 2025, June 18, 2025 and June 23, 2025 - $6.14, $7.08 and $7.99 for three and six months ended June 30, 2026.